Antitubercular Drug Development Strategies

Efforts to develop new therapies against tuberculosis combine target-centred discovery, innovative chemical scaffolds and advanced delivery systems. Central to modern programmes is the identification and validation of essential mycobacterial enzymes, including cell-wall arabinogalactan synthases and redox-dependent oxidoreductases. Nitroimidazole pro-drugs have emerged as a versatile class: once enzymatically activated, they release reactive species that compromise cell-wall integrity and disrupt redox homeostasis. Structure-based design of inhibitors against decaprenylphosphoryl-β-d-ribose epimerase subunits has yielded potent leads, while high-throughput genetic profiling has begun to elucidate resistance pathways. Parallel approaches exploit host-directed adjuncts to modulate immunity and accelerate bacterial clearance. Optimisation of pharmacokinetics and safety profiles has been supported by early bactericidal-activity studies in humans, informing dose selection for phase II trials. Formulation science now prioritises targeted pulmonary delivery to reduce systemic toxicity and improve adherence. Altogether, these strategies seek to shorten treatment, overcome multidrug-resistant strains and address latent infection reservoirs, thereby advancing global efforts to control and ultimately eliminate tuberculosis.

Research from Nature Portfolio

Recent studies have identified DprE2 as a direct target of bicyclic nitroimidazoles. By elucidating the interaction of activated pretomanid and delamanid with the DprE2 subunit, researchers have revealed a crucial NAD-adduct intermediate and validated decaprenylphosphoribose-2′-epimerase inhibition as a promising entry point for novel agents. Complementary metabolomic analyses have charted the unique perturbations induced by pretomanid in mycobacterial central metabolism, notably accumulation of pentose-phosphate intermediates and toxic methylglyoxal. This untargeted profiling has provided a systems-level map of drug action, guiding optimisation of pro-drug activation pathways and illuminating new vulnerabilities in bacterial physiology.

Antitubercular Drug Development Strategies publication trend

The graph below shows the total number of articles in antitubercular drug development strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Pro-drug: An inactive compound requiring enzymatic conversion within the pathogen to generate the active moiety.

Decaprenylphosphoribose-2′-epimerase (DprE2): A mycobacterial enzyme essential for arabinogalactan cell-wall synthesis and validated as a drug target.

F420 cofactor: A deazaflavin-based redox coenzyme involved in activation of nitroimidazole pro-drugs and protection against oxidative stress.

CRISPR screening: A high-throughput genetic approach that disrupts genes across the genome to identify determinants of drug susceptibility or resistance.

Early bactericidal activity (EBA): The initial reduction in sputum mycobacterial load over the first days of therapy, used to assess in vivo potency.

References

1. DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid. Nature Communications (2023).
2. Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824). Scientific Reports (2018).
3. CRISPR Screening and Comparative LC‐MS Analysis Identify Genes Mediating Efficacy of Delamanid and Pretomanid against Mycobacterium tuberculosis. Advanced Science (2024).
4. Inhalable Combination Powder Formulations for Treating Latent and Multidrug-Resistant Tuberculosis: Formulation and In Vitro Characterization. Pharmaceutics (2023).
5. Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832. Antimicrobial Agents and Chemotherapy (2023).